|
|
The safety, efficacy and resistance profile of Hepsera® (adefovir dipivoxil) are supported by data from key studies in several different patient populations, including those who had not previously received therapy, patients with lamivudine-resistant virus, patients with decompensated liver disease and patients with precore mutant hepatitis B (a strain of the virus that has evolved without the hallmark hepatitis B "e" antigen).1-6
|
|
 |
|
| 1-6 |
|
 |
|
|
Click here for full Prescribing Information.
|